Immunovant, Inc. Warrants expiring 12/18/2024

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch IMVTW and buy or sell other stocks, options, and ETFs commission-free!

About IMVTW

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. 

CEO
Peter Salzmann, MD, MBA
CEOPeter Salzmann, MD, MBA
Employees
Employees
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2018
Founded2018
Employees
Employees

IMVTW Key Statistics

Market cap
Market cap
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
Average volume
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
52 Week high
52 Week low
52 Week low
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.